ZiP Diagnostics co-founder Dr Jack Richards is delivering a keynote presentation at the AusBiotech Agribiotech & Biosecurity Summit on "Frontline Detection and Protection: The importance of point-of-care testing for real-time, data-driven agricultural biosecurity." ZiP's rapid point-of-care molecular tests for animal diseases enable farmers, vets and biosecurity officers to receive immediate results in the field, enabling targeted, data-driven management decisions as part of integrated biosecurity responses and improved surveillance for endemic diseases. As an Australian manufacturer, ZiP Diagnostics is committed to supporting national biosecurity efforts through domestic production capability. This sovereign manufacturing capacity enables rapid response to emerging threats while positioning Australia to deliver critical diagnostic solutions for our region and contribute to global disease containment efforts. Please join us at the summit on 23rd October!! https://lnkd.in/gU2PwWTy #AusBiotech #Biosecurity #AgTech #australianmanufacturer #SovereignCapability #AnimalHealth #pointofcarediagnostics #diagnosticsforglobalhealth #MolecularDiagnostics
ZiP Diagnostics
Medical Equipment Manufacturing
Collingwood, Victoria 1,019 followers
Point-of-care diagnostic solutions designed and manufactured in Australia
About us
ZiP Diagnostics is an Australian owned, Melbourne based biotech manufacturer that was established in 2019. ZiP’s mission is to improve health outcomes, improve healthcare efficiency and cost-effectiveness by developing rapid, accurate and low-cost point-of-care tests for human and animal applications. We proudly design and manufacture our innovative products at our world-class facilities in Melbourne, Australia, operating under ISO-13485 certified quality systems for vitro diagnostic products. ZiP’s unique capability is critical to secure the supply of important health products to meet Australia’s needs, and to provide a capability that can respond rapidly to novel outbreaks and threats.
- Website
-
www.zipdiag.com
External link for ZiP Diagnostics
- Industry
- Medical Equipment Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Collingwood, Victoria
- Type
- Privately Held
- Founded
- 2019
- Specialties
- BioTechnology, Point-Of-Care, Diagnostics, MedTech, Molecular Diagnostics, Human Health, Animal Health, Infectious Diseases, and Australian Manufacturing
Locations
-
Primary
Get directions
24 Cromwell St
Collingwood, Victoria 3066, AU
Employees at ZiP Diagnostics
-
Corrado Addessi
Executive Leader | Head of Marketing & Sales | Commercial Strategy | Business Development | Problem Solving | Negotiation | Dedicated to Building…
-
Jack Richards
Director at Zip Diagnostics
-
Riikka Arppe-Tabbara
Senior Research Officer - Lateral flow team manager at Zip Diagnostics
-
Christopher Mcwilliam
Senior Systems Engineer - Bachelor of Mechanical Engineering (Honours)/Bachelor of Industrial Design (Honours)
Updates
-
Water Contamination Testing: Rapid Field Diagnostics for Public Health Protection National Water Week celebrates water innovation and achievements supporting Australia's sustainable future. Among the critical challenges requiring innovative solutions is human sewage contamination of waterways – a growing public health and environmental concern, particularly in urban areas experiencing increased population density and climate-induced extreme weather events. Real-time field testing is essential for effective contamination monitoring and source tracking, enabling rapid public health responses and environmental management decisions. ZiP Diagnostics has developed the ZiP-P2 platform – a portable molecular diagnostic system capable of detecting sewage contamination markers directly in the field. Delivering accurate results in 10-20 minutes, the platform enables immediate directed sampling and source tracking investigations. Our Australian-made technology supports rapid response to contamination events, whether from infrastructure failures, extreme weather impacts, or other sources. We will be showcasing our field-deployable water tests at the WIOA Conference and Exhibition in Bundaberg, Queensland, 29-30 October. https://lnkd.in/gaxjQG7u #NationalWaterWeek #WaterQuality #EnvironmentalHealth #onehealth #PublicHealth #AustralianManufacturing #ClimateResilience #WaterTesting
-
-
ZiP Diagnostics is proud to be part of the Pathway to Market Program and we're looking forward to exhibiting at the AMMA Medtech Showcase, an event bringing together innovators, manufacturers, clinicians, and decision-makers to champion local capability, procurement and collaboration. Visit us at the showcase on 16th October. #pointofcarediagnostics #diagnosticsforglobalhealth #australianmanufacturer
-
-
ZiP Diagnostics reposted this
“We didn't just attend a conference; we validated a future for rapid diagnostics” The Changu syphilis test innovation, a project designed to radically speed up critical diagnosis has been recognized with the Third Best 2025 Innovation Award at the recent KUHeS Research Dissemination Conference (RDC). This award is the second major spotlight on "Collaborative Diagnostics Supporting Maternal and Child Health." For two full days, the innovation was inescapable. The news wasn't just reported, it dominated the media landscape. From the moment the story broke, it secured national headlines and became the definitive trending topic across all social media channels, turning public attention squarely onto the future of rapid diagnostics. Every major broadcast organization, Malawi Broadcasting Cooperation, Times Television, and Zodiak TV placed Changu innovation front and center, ensuring the details of this life-saving technology reached every corner of Malawi. This success belongs entirely to the power of partnership. A huge thank you to the Kamuzu University of Health Sciences (KUHeS),University of Melbourne and ZiP Diagnostics . This work is tangible proof that bridging local expertise with world-class scientific excellence creates unstoppable momentum. Think about the potential of moving diagnosis and treatment out of the central lab and directly to the community to protect mothers and newborns. This is a leap forward for accessibility and timely care. With this validation, our focus is laser-sharp on the next crucial steps. The journey to deployment is now full speed ahead. The conversation has started, and now the work begins. Read more about the project here https://lnkd.in/gcNiMbPA #HealthInnovation #KUHeS #GlobalHealth #SyphilisTesting #RDC2025 #MedicalDiagnostics #MaternalHealth #Innovation University of Melbourne Enterprising Melbourne Kamuzu University of Health Sciences Jack Richards Mona Taouk George Taiaroa AZZATO Franca Azzato
-
-
**Marking World Mosquito Day with Australian Diagnostic Innovation** World Mosquito Day commemorates British doctor Sir Ronald Ross's groundbreaking 1897 discovery that female mosquitoes transmit malaria between humans. Today, more than a century later, the battle against mosquito-borne diseases continues with Australian ingenuity leading innovative solutions. ZiP Diagnostics, an innovative Australian medtech manufacturer based in Melbourne, is developing next-generation point-of-care tests for infectious diseases. Through strategic investment from Health Security Systems Australia (a division of DMTC Ltd) and with support from Defence scientists, ZiP Diagnostics is collaborating with Australian manufacturer Axxin to develop an innovative point-of-care diagnostic platform for detection of mosquito borne infections. ZiP is leading the development of a multiplexed test capable of detecting multiple mosquito-borne infections from a single sample, including dengue fever, chikungunya, and malaria. As we mark World Mosquito Day today, this work takes on particular significance. Almost 700 million people contract a mosquito-borne disease every year, leading to over one million deaths annually. Since the beginning of 2025 alone, 3.6 million cases of dengue infection and over 1,900 dengue-related deaths have been reported across 94 countries worldwide. Our Australian-made solution will address a critical gap in global health infrastructure. ZiP's portable, field-ready diagnostic platform can deliver results rapidly, enabling immediate treatment and containment measures. The collaboration exemplifies Australian innovation at its best – combining local manufacturing expertise, strategic defence partnerships, and world-class research excellence to tackle global health challenges while strengthening Australia’s health and national security through enhanced biosurveillance capabilities. #onehealth #pointofcarediagnostics #diagnosticsforglobalhealth #australianmanufacturer #worldmosquitoday
-
-
ZiP Diagnostics point of care testing having an impact on improved health for cattle.
Great to see the ZiP Diagnostics team out doing farm testing for pestivirus this week. Testing almost 200 dairy cows in the day with time to result in 10-15 mins. This endemic disease of cattle is widespread in Australia and causing poor health of cattle, abortions and poor productivity on farms. Another good example of the benefit from point-of-care testing.
-
-
ZiP Diagnostics reposted this
It's great to be in Newcastle with ZiP Diagnostics for the Water Industry Operations Association of Australia (WIOA) Conference. If you're at the event come down and have a chat.
-
-
ZiP Diagnostics will be attending the 2025 NSW Water Industry Operations Conference & Exhibition held at Newcastle Jockey Club Racecourse from Wednesday 23 July to Thursday 24 July 2025. This conference is practical, hands-on and created for the people who actually run the water systems - operators, technicians, and front-line staff. https://hubs.li/Q03xNDWh0 Meet face-to-face with our team at Stand 33. We look forward to creating new connections around our water testing solutions and talking rapid diagnostics with you! #rapiddiagnostics #watertesting #WIOA
-
-
ZiP Diagnostics is very proud to be a recipient of funding under the MTPConnect TTRA program, to develop a point-of-care test for preeclampsia for global health impact for mothers and babies. Thankful to our partners Shaun Brennecke at Royal Women’s Hospital and Holger Unger at the Menzies School of Health Research. And congratulations to all the other recipients!! #mtpconnect #australianmanufacturer #pointofcarediagnostics #global health
📢 NEWS: MTPConnect’s Targeted Translation Research Accelerator Drugs and Devices program is investing $12 million to back 14 homegrown life science companies developing new medical devices and drugs that aim to reduce the burden of cardiovascular disease and complications of diabetes (type 1 and type 2) for patients, carers, families and communities. The announcement was made during the #BIO International Convention in Boston, one of the world’s biggest biotech events bringing together sector leaders from Australia and around the world. MTPConnect CEO Stuart Dignam said this funding injection is critical to backing Australian innovations to tackle these significant chronic health problems and scale in our backyard rather than offshore. “MTPConnect’s investment, combined with the matching industry contributions, represents a near $30 million downpayment on the future of Australia’s brilliant life science innovators. “In addition to vital funding, these 14 companies will receive ongoing acceleration support through mentoring and access to specialist advice from MTPConnect, and guidance from our industry impact partners, CSL and #RocheDiagnosticsAustralia so they can tap into the best of global industry expertise. “We’re particularly pleased that 50 per cent of the funded SMEs are organisations led by women which is well above the representation of women in senior management (26%) or CEO roles (10%) within STEM industries in Australia.” Congratulations to the following companies based in New South Wales, South Australia, Tasmania, Victoria and Western Australia: ✨ TTRA Drugs Investment Outcomes: Anaxis Pharma, Argenica Therapeutics, Aspecthera, Atherid Therapeutics, Endo Axiom, Inosi Therapeutics Pty Ltd, Nanomedx, ProGenis Pharmaceuticals ✨ TTRA Devices Investment Outcomes: CathRx, IDE Group, Theia Medical Pty Ltd, Venstra Medical, Wavewise Analytics (Formerly Cyban), ZiP Diagnostics Find out more about the companies’ innovation projects in the full announcement here. https://lnkd.in/g8PwZ8sM The TTRA program is delivered on behalf of the Medical Research Future Fund. Lauren Eve Kelly, Erin McAllum, Elise Needham PhD GAICD, Dharmica Mistry (PhD, GAICD)The Hon. Jaala Pulford GAICD
-
-
ZiP Diagnostics is pleased to be exhibiting at POC25 in Bangkok, Thailand on 19-21 June. The conference is bringing together leading experts, healthcare professionals, and researchers from across the Asia-Pacific region and will showcase innovations in point-of-care (POC) testing and address strategies for equitable access and healthcare integration. ZiP Diagnostics' mission is to provide rapid, high-performance and low cost POC diagnostics for global human health, animal health and environmental applications and we look forward to showcasing our innovative technologies - visit our booth! https://hubs.li/Q03slG_R0 #onehealth #pointofcarediagnostics #diagnosticsforglobalhealth #australianmanufacturer
-